ATLASATLAS fair value
SEK 159.56
Above fair value · 27% premium
Range: SEK 116–SEK 219Fair valuePrice
Xvivo Perfusion (XVIVO.ST)
Xvivo Perfusion stock price today, ATLAS forecast and fair value
Healthcare · Medical Devices · Nasdaq Stockholm · Sweden
SEK 202.00▼ -0.10%
Prices as of Oct 27, 2026 · SEK
Chance of rising in 1 month
49%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Xvivo Perfusion in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Xvivo Perfusion
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS estimates Xvivo Perfusion's fair value at about SEK 159.56 per share (reasonable range: SEK 116.04 to SEK 219.39). At SEK 202.00, the stock trades 27% above it.
It is calculated with a blend of a discounted cash-flow model and peer valuation multiples. Confidence in the estimate is medium. It is an estimate, not a promise: if the company's results change, so does its fair value.
ATLAS's model gives Xvivo Perfusion a 49% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between SEK 186.96 and SEK 217.33; in 9 out of 10, between SEK 163.61 and SEK 248.34. Estimated annual volatility is 41%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- SEK 6.9B
- Market cap (USD)
- $695M
- P/E ratio
- 79.2
- 52-week high
- SEK 314.80
- 52-week low
- SEK 160.10
- Revenue (12 months)
- SEK 895M
- Gross margin
- 72.3%
- Operating margin
- 10.5%
- Net margin
- 9.9%
- Beta
- 1.47
What this means
These are two different questions: fair value looks at the business (what it is worth given what it earns) and the odds look at the price over the next month. Xvivo Perfusion sits above fair value and its odds of rising over a month are close to a coin flip. An expensive stock can keep climbing and a cheap one can keep falling, which is why ATLAS shows the two readings separately.
Over the last 52 weeks XVIVO.ST has traded between SEK 160.10 and SEK 314.80. Today it is 35.8% below that high and 26% above its low.
On the business: net margin is 9.9%; it trades at 79.2 times earnings.
Its beta is 1.47: it tends to move more than the market, both up and down.
About the company
Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments.
Want to see everything about Xvivo Perfusion?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What is Xvivo Perfusion (XVIVO.ST) fair value?
About SEK 159.56 per share according to ATLAS (reasonable range: SEK 116.04 to SEK 219.39). With the stock at SEK 202.00, it is 27% above it.
What is the chance XVIVO.ST goes up next month?
49%: close to a coin flip. In half of the simulated outcomes, XVIVO.ST ends the month between SEK 186.96 and SEK 217.33.
How big is Xvivo Perfusion and what is its P/E ratio?
Xvivo Perfusion's market capitalization is SEK 6.9B. Its price-to-earnings (P/E) ratio is 79.2: you pay SEK 79.2 for each SEK 1.00 of yearly earnings.
How volatile is XVIVO.ST?
ATLAS estimates annual volatility at 41%. In a typical month, half of the outcomes end between SEK 186.96 and SEK 217.33.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer